Humanwell Healthcare (600079.SH): Brexpiprazole Tablets Obtain Drug Registration Certificate
ST Renfu (600079.SH) announced that its holding subsidiary Yichang Renfu Pharmaceutical Co., Ltd. (referred to as "Yichang Renfu," in which the company holds an 80% stake) recently received the "Drug Registration Certificate" for Brivaracetam Tablets issued by the National Medical Products Administration.
Humanwell Healthcare (600079.SH) announced that its subsidiary, Yichang Rendu Pharmaceutical Co., Ltd. (referred to as "Yichang Rendu," in which the company holds an 80% stake), recently received the drug registration certificate for Brexpiprazole from the National Medical Products Administration.
Brexpiprazole is primarily used for the treatment of adult schizophrenia. Yichang Rendu submitted its application for market approval of Brexpiprazole to the National Medical Products Administration in April 2025, which has been accepted. To date, the total R&D investment for this project has amounted to approximately 18 million RMB.
Related Articles
SHENZHENEXPRESS (00548) plans to issue 1 billion yuan in medium-term notes.
Yangfan New Materials (300637.SZ) plans to repurchase company shares with an outlay of 30 million to 60 million yuan.
WK GROUP (02535) appointed First Capital as its independent financial advisor.
SHENZHENEXPRESS (00548) plans to issue 1 billion yuan in medium-term notes.
Yangfan New Materials (300637.SZ) plans to repurchase company shares with an outlay of 30 million to 60 million yuan.
WK GROUP (02535) appointed First Capital as its independent financial advisor.
RECOMMEND
